LEXINGTON, Mass. & LEIDEN, Netherlands--(BUSINESS WIRE)--Synageva BioPharma Corp. and to-BBB technologies BV, the Dutch drug brain delivery company, have entered into a research collaboration to evaluate the potential of transporting therapeutic proteins across the blood-brain barrier into the central nervous system (CNS). The blood-brain barrier, a protective filter for the CNS, can be an obstacle for protein therapeutics and prevent these treatments from reaching their site of action within the CNS. A number of rare diseases that could benefit from protein therapeutics have a CNS component and require the therapies to be transported across the blood-brain barrier. This research collaboration will be the basis for a development program for therapies for multiple such rare diseases, including Lysosomal Storage Diseases (LSDs).
